Preeclampsia is a common pregnancy complication, affecting 2% to 8% of pregnancies
worldwide, and is an important cause of both maternal and fetal morbidity and mortality …

Fetal growth restriction (FGR) in human pregnancy is associated with perinatal mortality,
short-and long-term morbidities. No prenatal therapy is currently established despite …

Preeclampsia affects∼ 2–8% of pregnancies worldwide. It is associated with increased long-
term maternal cardiovascular disease risk. This study assesses the effect of the …

In vivo studies on the pathology of gestation, including preeclampsia, often use small
mammals such as rabbits or rodents, ie, mice, rats, hamsters, and guinea pigs. The key …

Preeclampsia (PE) is a multisystemic, pregnancy-specific disorder and a leading cause of
maternal and fetal death. PE is also associated with an increased risk for chronic morbidities …

Physiological or pathological hypoperfusion of the placenta is one of the main causes of
intrauterine growth restriction (IUGR) which poses a significant risk to the health of the fetus …

Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor with a long half-life, high selectivity, and
rapid onset of action. Because the safety of using PDE5 inhibitors as therapeutic agents for …

Introduction Animal models are indispensable tools in studying the mechanisms underlying
the diseases. Rat models with reduced uterine perfusion pressure (RUPP) were able to …

Introduction We aimed to examine the effect of uterine arterial (UtA) blood flow changes after
tadalafil treatment for fetal growth restriction (FGR) using two-dimensional (2D) phase …

Background–Tadalafil, a long-acting phosphodiesterase 5 (PDE5) inhibitor, alleviates
preeclampsia (PE), and decreases the fetal and infant deaths associated with fetal growth …